Masked Hypertension in CKD: Increased Prevalence and Risk for Cardiovascular and Renal Events.


Journal

Current cardiology reports
ISSN: 1534-3170
Titre abrégé: Curr Cardiol Rep
Pays: United States
ID NLM: 100888969

Informations de publication

Date de publication:
20 05 2019
Historique:
entrez: 22 5 2019
pubmed: 22 5 2019
medline: 23 2 2020
Statut: epublish

Résumé

Hypertension and chronic kidney disease (CKD) are inextricably linked. The causal nature of the relationship is bidirectional. This relationship holds when blood pressure is assessed in the clinic and outside the clinic with home and ambulatory blood pressure monitoring. Patients with CKD are more likely to have high-risk hypertension phenotypes, such as masked and sustained hypertension, and are at increased risk for cardiovascular disease. The purpose of this review is to describe the increased prevalence of masked hypertension in patients with CKD and then describe the increased risk for target organ damage and adverse clinical events associated with masked hypertension in patients with CKD. The prevalence of masked hypertension is greater in patients with CKD than that of the general population. Recent studies have demonstrated that masked hypertension is associated with increased risk for target organ damage including left ventricular hypertrophy, elevated pulse wave velocity, proteinuria, and decreased estimated glomerular filtration rate in patients with CKD. Additionally, in patients with CKD, masked hypertension is associated with increased risk for cardiovascular disease, end-stage renal disease, and all-cause mortality. Patients with CKD are at increased risk for masked hypertension. Masked hypertension is associated with increased risk for target organ damage and adverse cardiovascular and renal outcomes in patients with CKD. Further research is necessary to better understand the pathophysiology of masked hypertension, the optimal method for diagnosing masked hypertension, and to determine whether masked hypertension is a modifiable risk factor.

Identifiants

pubmed: 31111326
doi: 10.1007/s11886-019-1154-4
pii: 10.1007/s11886-019-1154-4
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

58

Références

Clin J Am Soc Nephrol. 2012 Nov;7(11):1770-6
pubmed: 22935847
Clin J Am Soc Nephrol. 2016 Apr 7;11(4):642-52
pubmed: 26912547
Nephrol Dial Transplant. 2017 Oct 1;32(10):1710-1717
pubmed: 27422961
Am J Kidney Dis. 2010 Mar;55(3):441-51
pubmed: 19962808
Hypertension. 2014 Nov;64(5):935-42
pubmed: 25135185
JAMA. 2004 Mar 17;291(11):1342-9
pubmed: 15026401
J Hypertens. 2013 Jun;31(6):1136-43
pubmed: 23466942
Eur Heart J. 2017 Apr 14;38(15):1112-1118
pubmed: 27836914
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Clin J Am Soc Nephrol. 2009 Mar;4(3):656-64
pubmed: 19261815
Hypertens Res. 2010 Nov;33(11):1192-8
pubmed: 20703228
Am J Hypertens. 2007 Apr;20(4):385-91
pubmed: 17386344
Am J Kidney Dis. 2012 Sep;60(3):449-62
pubmed: 22521624
J Hypertens. 2007 Nov;25(11):2193-8
pubmed: 17921809
Ann Intern Med. 1999 Oct 19;131(8):564-72
pubmed: 10523216
J Hum Hypertens. 2017 Sep;31(9):545-546
pubmed: 28790438
Nephrol Dial Transplant. 2009 Aug;24(8):2400-6
pubmed: 19251741
Hypertension. 2009 Jan;53(1):20-7
pubmed: 19047584
Ann Intern Med. 2015 Nov 17;163(10):778-86
pubmed: 26458123
Am J Hypertens. 2008 Sep;21(9):969-75
pubmed: 18583985
J Hypertens. 2018 Jul;36(7):1524-1532
pubmed: 29601413
Lancet. 2013 Jul 27;382(9889):339-52
pubmed: 23727170
Am J Nephrol. 2006;26(5):503-10
pubmed: 17124383
J Am Soc Nephrol. 2017 Feb;28(2):671-677
pubmed: 27516235
Kidney Int. 2006 Apr;69(7):1175-80
pubmed: 16467785
Am J Kidney Dis. 2014 Nov;64(5):744-52
pubmed: 25082100
Kidney Int. 2006 Jan;69(2):406-11
pubmed: 16408134
Curr Hypertens Rep. 2017 Oct 25;19(12):94
pubmed: 29071520
Nephrology (Carlton). 2016 Oct;21(10):841-50
pubmed: 26566951
Clin J Am Soc Nephrol. 2013 May;8(5):721-30
pubmed: 23411432
Ann Intern Med. 2005 Mar 1;142(5):342-51
pubmed: 15738453
Am J Med. 2008 Apr;121(4):332-40
pubmed: 18374693
N Engl J Med. 2018 Apr 19;378(16):1509-1520
pubmed: 29669232
Int J Cardiol. 2017 Mar 1;230:33-39
pubmed: 28034462
Circ J. 2009 Aug;73(8):1381-5
pubmed: 19602774
Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1348-1357
pubmed: 29976600
Minerva Urol Nefrol. 2013 Mar;65(1):37-50
pubmed: 23538309
Hypertension. 2017 Jan;69(1):42-50
pubmed: 27849563
Hypertens Res. 2017 Jan;40(1):87-95
pubmed: 27511054
J Hum Hypertens. 2014 Feb;28(2):74-9
pubmed: 23803592
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272

Auteurs

Megha Babu (M)

Essentia Health, Fargo, ND, USA.

Paul Drawz (P)

Division of Renal Diseases & Hypertension, University of Minnesota, 717 Delaware St SE, Suite 353, Minneapolis, MN, 55414, USA. draw0003@umn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH